David Rimm

David Rimm is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an M.D.-Ph.D. at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. At Yale since 1994, Dr. Rimm is the Director of Yale Pathology Tissue Services. He is a member of the Executive Team in Pathology and serves as the Director of Translational Pathology.

His lab group focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy or recurrence or metastasis in breast and lung cancer and melanoma. The technology has also been used in a series of efforts related to biospecimen science. He is also beginning efforts on new high-plex technologies, including Imaging Mass Cytometry and Digital Spatial Profiling. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biotech and pharma.

He is a member of a number of correlative science committees for multi-institutional breast cancer clinical trials including SWOG, ALLTO, and TEACH. He also serves on the Molecular Oncology committee for the College of American Pathologists (CAP). He is an author of over 380 peer-reviewed papers and 8 patents. He has served on advisory boards for Amgen, Lilly, Novartis, Astra Zeneca, BMS, Cepeid, Perkin Elmer, Dako, Ventana, PAIGE.AI and Cell Signaling Technology. He was a scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.